Fineline Cube

Follow:
14486 Articles
Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2‑Positive Colorectal Cancer
CompanyDrug

Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2‑Positive Colorectal Cancer

Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14
CompanyDrug

Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14

Sichuan Kelun‑Biotech Wins NMPA Approval for Sacituzumab‑Tirumotecan in EGFR‑Mutant Lung Cancer
CompanyDrug

Sichuan Kelun‑Biotech Wins NMPA Approval for Sacituzumab‑Tirumotecan in EGFR‑Mutant Lung Cancer

Beihai Biotech Secures FDA IND Approval for First‑In‑Class Peptide‑Drug Conjugate BH1621
CompanyDrug

Beihai Biotech Secures FDA IND Approval for First‑In‑Class Peptide‑Drug Conjugate BH1621

Sichuan Biokin’s SystImmune Receives $250 Million Triggered by Phase 2/3 Milestone in EGFR×HER3 ADC
CompanyDeals

Sichuan Biokin’s SystImmune Receives $250 Million Triggered by Phase 2/3 Milestone in EGFR×HER3 ADC

Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis
Drug

Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis

China’s NMPA Approves Mufemilast (Hemay005) — Hemei’s First Domestic PDE4 Inhibitor
Drug

China’s NMPA Approves Mufemilast (Hemay005) — Hemei’s First Domestic PDE4 Inhibitor

State Council Introduces 2026 Regulations Governing Clinical Research of Biomedical New Technologies in China
DrugMedical Device

State Council Introduces 2026 Regulations Governing Clinical Research of Biomedical New Technologies in China

BMS Acquires Orbital for $1.5 B in RNA‑Based Immunotherapy Deal
CompanyDeals

BMS Acquires Orbital for $1.5 B in RNA‑Based Immunotherapy Deal

Peijia Medical Secures NMPA Approval for GeminiOne TEER System
CompanyMedical Device

Peijia Medical Secures NMPA Approval for GeminiOne TEER System

PegBio Signs Non‑Binding Term Sheet with UAE‑Based PDC for Exclusive Middle East & Africa License of Visepegenatide
CompanyDeals

PegBio Signs Non‑Binding Term Sheet with UAE‑Based PDC for Exclusive Middle East & Africa License of Visepegenatide

Tigermed Completes Share Transfer of Teddy Clinical Laboratory to Frontage Laboratories for RMB 270 Million
CompanyDeals

Tigermed Completes Share Transfer of Teddy Clinical Laboratory to Frontage Laboratories for RMB 270 Million